Overexpression and translocation of dynamin 2 promotes tumor aggressiveness in breast carcinomas

Authors

  • Roya Sajed Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medicine Sciences (IUMS), Tehran, Iran; Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
  • Leili Saeednejad Zanjani Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
  • Mandana Rahimi Hasheminejad Kidney Center, Pathology Department, Iran University of Medical Sciences (IUMS), Tehran, Iran
  • Maryam Mansoori Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medicine Sciences (IUMS), Tehran, Iran; Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
  • Amir-Hassan Zarnani Department of Immunology, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran; Reproductive Immunology Research Center, Avicenna Research Institute (ACECR), Tehran, Iran
  • Zahra Madjd Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medicine Sciences (IUMS), Tehran, Iran; Tel/Fax: +982188622608; E-mail: majdjabari.z@iums.ac.ir; zahra.madjd@yahoo.com
  • Roya Ghods Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medicine Sciences (IUMS), Tehran, Iran; Tel/Fax: +982186704837; E-mail: ghods.ro@iums.ac.ir; rghods77@yahoo.com

DOI:

https://doi.org/10.17179/excli2020-2762

Keywords:

dynamin 2, breast cancer, immunohistochemistry, tissue microarray (TMA), invasion, cancer progression

Abstract

Dynamin 2 is a GTPase protein that has been implicated in cancer progression through its various roles such as endocytosis, morphogenesis, epithelial-mesenchymal transition (EMT), cellular contractions, and focal adhesion maturation. The increased expression levels of this molecule have been demonstrated with the development of several cancers such as prostate, pancreas, and bladder. However, its clinical significance in breast cancer is unclear yet. In the present study, the membranous, cytoplasmic, and nuclear expression levels of dynamin 2 molecule were evaluated for the first time, using immunohistochemistry (IHC) on tissue microarray (TMA) slides in 113 invasive breast cancer tissues. Moreover, afterward, the association between the dynamin 2 expression and clinicopathological features was determined. Our finding showed that, a higher nuclear expression of dynamin 2 is significantly associated with an increase in tumor stage (P = 0.05), histological grade (P = 0.001), and age of the patients (P = 0.03). In addition, analysis of the cytoplasmic expression levels of this molecule revealed that, there was a statistically significant difference between the expression levels of dynamin 2 among the different breast cancer subtypes (P = 0.003). Moreover, a significant association was found between the increased expression of dynamin 2 membranous and vascular invasion (VI) (P = 0.02). We showed that dynamin 2 protein expression has an association with more aggressive tumor behavior and more advanced disease in the patients with breast cancer; therefore, dynamin 2 molecule could be considered as an indicator of disease progression and aggressiveness.

Published

2020-10-29

How to Cite

Sajed, R., Saeednejad Zanjani, L., Rahimi, M. ., Mansoori, M. ., Zarnani, A.-H. ., Madjd, Z. ., & Ghods, R. (2020). Overexpression and translocation of dynamin 2 promotes tumor aggressiveness in breast carcinomas. EXCLI Journal, 19, 1423–1435. https://doi.org/10.17179/excli2020-2762

Issue

Section

Original articles

Most read articles by the same author(s)